IP Library Patent Application 10526377
Patent Application
App. No. 10/526,377

Hypogastric and/or perineal pain-relieving agent

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/526,377
Abstract

A pharmaceutical composition for improving chronic pelvic cavity pain syndrome due to urinary dysfunction where said composition contains tamsulosin or pharmaceutically acceptable salts thereof.

Claims (7)

1 . A pharmaceutical composition for improving chronic pelvic cavity pain syndrome due to urinary dysfunction where said composition contains tamsulosin or pharmaceutically acceptable salts thereof.

2 . A pharmaceutical composition for improving hypogastric/perineal pain due to a state of decreased urine production where said composition contains tamsulosin or pharmaceutically acceptable salts thereof.

3 . A pharmaceutical composition for improving chronic pelvic cavity pain syndrome due to urinary dysfunction according to claim 1 where said composition contains tamsulosin hydrochloride.

4 . Use of tamsulosin or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for improving chronic pelvic cavity pain syndrome due to urinary dysfunction.

5 . Use of tamsulosin or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for improving hypogastric/perineal pain or lower backache due to a state of decreased urine production.

6 . A method for the therapy of chronic pelvic cavity pain syndrome due to urinary dysfunction, where said method includes the administration of effective therapeutic doses of tamsulosin or a pharmaceutically acceptable salt thereof to patients.

7 . A method for the therapy of hypogastric/perineal pain or lower backache due to a state of decreased urine production, where said method includes the administration of effective therapeutic doses of tamsulosin or a pharmaceutically acceptable salt thereof to patients.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2005
From: FURUDATE, NAOMICHI; SHIMOYAMA, MITSURU
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 017106/0347 →